His scientific interests lie mostly in Internal medicine, Immunology, Oncology, Surgery and Dendritic cell. His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology. His research integrates issues of Cytotoxic T cell and Chemotaxis in his study of Immunology.
His Oncology research is multidisciplinary, incorporating perspectives in Prostate cancer and Hazard ratio. His Surgery study integrates concerns from other disciplines, such as Placebo and Pazopanib. His Dendritic cell research is multidisciplinary, incorporating elements of Interleukin 3, Antigen-presenting cell and Chemokine.
Internal medicine, Oncology, Prostate cancer, Immunology and Renal cell carcinoma are his primary areas of study. His Internal medicine research integrates issues from Gastroenterology and Surgery. His research in Oncology intersects with topics in Castration resistant, Enzalutamide and Phases of clinical research.
His study in Prostate cancer is interdisciplinary in nature, drawing from both Prostate and Docetaxel. He has included themes like Cytotoxic T cell and Melanoma in his Immunology study. His Renal cell carcinoma research includes elements of Carcinoma and Nephrectomy.
His primary areas of investigation include Internal medicine, Prostate cancer, Oncology, Clinical trial and Renal cell carcinoma. His is doing research in Clinical endpoint, Chemotherapy, Hazard ratio, Progression-free survival and Carboplatin, both of which are found in Internal medicine. He regularly links together related areas like Docetaxel in his Prostate cancer studies.
Ian D. Davis works in the field of Oncology, namely Adjuvant. His Clinical trial study combines topics from a wide range of disciplines, such as Quality of life and Family medicine. Ian D. Davis studied Renal cell carcinoma and Nivolumab that intersect with Ipilimumab.
Ian D. Davis mainly focuses on Prostate cancer, Internal medicine, Oncology, Clinical endpoint and Cabazitaxel. His studies in Prostate cancer integrate themes in fields like PET-CT, Nuclear medicine, Docetaxel and Consensus conference. Ian D. Davis undertakes interdisciplinary study in the fields of Internal medicine and Context through his research.
Ian D. Davis focuses mostly in the field of Oncology, narrowing it down to topics relating to MEDLINE and, in certain cases, Surgical excision. His Progression-free survival research incorporates elements of Darolutamide and Apalutamide. His Chemotherapy research is multidisciplinary, relying on both Gastroenterology and Placebo.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg;Ian D. Davis;Jozef Mardiak;Cezary Szczylik.
Journal of Clinical Oncology (2010)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot.
The New England Journal of Medicine (2014)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Ian D. Davis;Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente.
Proceedings of the National Academy of Sciences of the United States of America (2004)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Cora N. Sternberg;Robert E. Hawkins;John Wagstaff;Pamela Salman.
European Journal of Cancer (2013)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran.
European Urology (2018)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis;Andrew J. Martin;Martin R. Stockler;Martin R. Stockler;Stephen Begbie.
The New England Journal of Medicine (2019)
Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
M.E. Gleave;M. Elhilali;Y. Fradet;I. Davis.
The New England Journal of Medicine (1998)
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson;Ian D. Davis;Jean-Pascal H. Machiels;Paul L. De Souza.
Journal of Clinical Oncology (2010)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen;A Omlin;G Attard;J S de Bono.
Annals of Oncology (2015)
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg.
Lancet Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: